Institut National du Cancer

What Institut National du Cancer does

Institut National du Cancer (INCa) is the French national cancer agency, established in 2005 as an établissement public administratif under the supervision of the French Ministry of Health. It functions as the country's state-level expertise and coordination body for oncology, serving patients, caregivers, healthcare professionals, researchers, and the broader public. INCa's remit spans prevention, screening, research funding and coordination, clinical guideline production, drug safety monitoring, and epidemiological surveillance. It coordinates the French government's 2021-2030 Décennal Cancer Strategy, through which it administers €1.74 billion in public investment.

The institute's product surface is built around three principal assets: (1) cancer.fr, France's official reference information portal on cancers, complemented by the screening portal jefaismondepistage.fr; (2) data and clinical trial infrastructure including the Registre national des cancers (RNC), the Plateforme de données en cancérologie (PDC), and the Registre des essais cliniques; and (3) programmatic initiatives such as the IMPULSION lung cancer screening pilot (20,000 volunteers across 5 regions) and the Cancer Info anonymous helpline (0805 123 124). Distribution is multi-channel: toll-free helpline, digital self-service portals, social media, the "Les Rencontres de l'Institut" events, and an ecosystem of more than 1,800 oncology-authorized healthcare establishments, 7 regional cancéropôles, and the SIRIC integrated research sites.

INCa's business model is government-funded rather than commercial. As a state agency it does not sell products or services; its screening programs and information services are provided free to French citizens, and all operating expenses are met through French state budget allocations. The institute distributes research funding to French and international partners (including joint work with the U.S. National Cancer Institute, ICRP, and Cancer Grand Challenges) and operates European collaborations (CHRODIS+, T2EVOLVE, TRANSCAN). Its strategic partners also include LigueContreLeCancer for Cancer Info service delivery and regional health agencies (ARS) for local implementation.

Name

Institut National du Cancer

Legal name

Institut national du cancer

Website

https://e-cancer.fr

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

101–250 employees

Short description

Institut National du Cancer (INCa) is the French state agency coordinating national cancer control: prevention, screening, research funding, clinical guidelines, and the national cancer registry, serving patients, healthcare professionals, researchers, and the French public since 2005.

Ownership category

akta.pro rank

Product category

National Cancer Control and Public Health Services

NAICS

Public Administration (92)

SIC

Services-Health Services (8000), International Affairs (9721)

akta.pro primary industry

Program Monitoring, Evaluation & Learning (MEL) (HLAJANAA)

akta.pro secondary industries

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF)

Keywords

• Cancer prevention programs
• Cancer screening coordination
• National cancer registry
• Clinical practice guidelines
• Cancer research funding

Headquarters

HQ city

Boulogne-billancourt

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Government funding: As a French state agency, the Institut National du Cancer operates under public health ministry oversight and is funded through government budget allocations. The institute coordinates the Décennal Cancer Strategy 2021-2030, managing public resources for cancer prevention, research, and care optimization.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Institut National du Cancer (INCa) is a French state agency that coordinates national cancer control efforts, including prevention programs, screening campaigns (breast, colorectal, cervical, and a lung cancer pilot), clinical practice guidelines, epidemiological surveillance via the national cancer registry, and cancer research funding. It operates the cancer.fr information portal, the Cancer Info helpline (0805 123 124), and the clinical trials registry as primary public service touchpoints.

Product overview

Institut National du Cancer operates cancer.fr, a comprehensive information and services platform that serves as France's primary reference resource for cancer-related information. The offering consists of an information portal (cancer.fr) providing educational content on cancer types, prevention, screening, and treatment pathways, complemented by several dedicated services: the Cancer Info telephone service (0805 123 124) for personalized support; the National Cancer Registry (Registre National des Cancers) for epidemiological data; a Clinical Trials Registry for research access; and the IMPULSION pilot screening program for lung cancer. These services collectively support patients, caregivers, healthcare professionals, and researchers in cancer prevention, early detection, and care management.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer.fr Website Portal Comprehensive web portal providing authoritative information on cancers, including prevention, screening, diagnosis, treatment, patient pathways, care support, and after-cancer care, serving patients, caregivers, healthcare professionals, and the general public in France.
• Cancer Info Service Free, anonymous telephone information service (0805 123 124) staffed by information officers who answer practical, medical, and social questions from patients, survivors, and caregivers across France.
• Registre National des Cancers National cancer registry providing comprehensive data on cancer incidence, prevalence, and outcomes in France, including a data catalog with available datasets, data sharing mechanisms, and studies utilizing the registry data for researchers and public health authorities.
• Registre des Essais Cliniques Public registry of clinical trials in oncology, allowing patients and healthcare professionals to search and access information about ongoing cancer clinical studies in France.
• Programme IMPULSION Pilot lung cancer screening program (IMPémentation du dÉpistage du cancer PULmonaire en populatION) testing low-dose thoracic CT scanning combined with smoking cessation support among 20,000 volunteers aged 50-74 across Île-de-France, Hauts-de-France, Pays de la Loire, Provence-Alpes-Côte d'Azur, and Auvergne-Rhône-Alpes.
• Catalogue des Publications Online catalog of publications, reports, and educational materials produced by the Institut National du Cancer, available for healthcare professionals, patients, and the general public.

Quantifiable outcome

• IMPULSION program aims to test lung cancer screening that could reduce lung cancer mortality by 20-25%
• +1 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered major, moderate and core.

• Cancer Grand ChallengesmajorStrategic or Co-development PartnerInternational research partnership program tackling significant challenges in cancer. The institute participates as part of France's involvement in this global initiative to fund transformative cancer research.
• CHRODIS+moderateStrategic or Co-development PartnerEuropean joint action focused on chronic diseases, including cancer prevention and care optimization. Supports implementation of best practices across EU member states.
• ICRP (International Cancer Research Partnership)majorStrategic or Co-development PartnerInternational partnership enabling coordination of cancer research funding and data sharing among member organizations globally. Allows harmonized research data and reduced duplication.
• National Cancer Institute (NCI) - United StatesmajorStrategic or Co-development PartnerBilateral cooperation with the U.S. National Cancer Institute for clinical research collaboration, knowledge exchange, and joint initiatives in cancer research.
• T2EVOLVEmoderateStrategic or Co-development PartnerEuropean research project focused on immuno-oncology and CAR-T cell therapy evaluation. Part of efforts to advance innovative cancer treatment assessment.
• TRANSCAN (European Cancer Research Area)moderateStrategic or Co-development PartnerERA-NET program supporting transnational cancer research collaboration. Enables joint funding of research projects across European countries.
• Les cancéropôlescoreStrategic or Co-development PartnerSeven regional cancer research clusters (cancéropôles) that structure and federate cancer research across France, coordinating activities within their geographic areas.
• Les SIRIC (Sites de Recherche Intégrée sur le Cancer)coreStrategic or Co-development PartnerIntegrated cancer research sites that bring together clinical research, translational research, and care delivery within designated hospital-university campuses.
• LigueContreLeCancercoreStrategic or Co-development PartnerPartnership with France's largest cancer charity for Cancer Info service delivery, combining the institute's governmental expertise with the league's patient support network.
• Les établissements autorisés en cancérologiecoreImplementation/ SI/ Consulting PartnerNetwork of over 1,800 healthcare establishments authorized by regional health agencies for cancer diagnosis and treatment, implementing national protocols and screening programs.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Canadian Cancer Society: Canada's national cancer charity funding research and delivering public information and support services; comparable in scope to INCa as a national reference body for cancer information and prevention, but operating in a different geography.
• Cancer Council Australia: Australia's leading national cancer non-profit combining research funding, prevention programs, and public information; mirrors INCa's coordination of prevention, screening, and information functions for a single national population.
• KWF Dutch Cancer Society: Netherlands' leading cancer charity funding research, prevention campaigns, and patient support; comparable in mission (cancer research, public information, prevention) to INCa's national mandate, but operating in a different national market.
• Dutch Cancer Registry (NCR): Operated by IKNL, the Netherlands' national cancer registry is a direct functional analog to INCa's Registre national des cancers, providing population-level cancer incidence and outcomes data for a single national population.
• Swiss Cancer League (Krebsliga): Switzerland's national cancer umbrella organization running prevention campaigns, screening programs, and patient support services; mirrors INCa's information, prevention, and screening coordination functions but in a different national market.

Direct peers

• European Cancer Organisation (ECO): Pan-European not-for-profit umbrella organization coordinating cancer control stakeholders across EU member states; comparable to INCa as a convening and policy-shaping body, but operating at the European rather than national level.
• Cancer Research UK: The UK's largest cancer research and awareness charity, funding research, operating clinical trials information, and running public information services — closely mirroring INCa's combined information, registry, and research coordination functions for a single national population.
• German Cancer Research Center (DKFZ): Germany's national biomedical research institute focused on cancer; comparable to INCa as a publicly funded cancer research and information backbone, with significant translational research and epidemiological capabilities that parallel INCa's national research mandate.
• International Agency for Research on Cancer (IARC): WHO's specialized cancer research agency based in Lyon; directly comparable to INCa as a public-sector cancer data and epidemiology organization, operating global cancer registries and producing classifications that INCa's national registry relies on.

Broad incumbents

• U.S. National Cancer Institute (NCI): The U.S. federal agency for cancer research and training; a direct bilateral partner of INCa with an overlapping mandate across research funding, clinical trials, and population-level cancer control. INCa explicitly cooperates with NCI under a major strategic alliance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Institut_cancer
• YouTubeyoutube.com/user/inca
• Facebookfacebook.com/Mobilisons.nous
• LinkedInlinkedin.com/company/institut-national-du-cancer
• Instagraminstagram.com/institut_national_du_cancer

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut National du Cancer